Abbott Laboratories (ABT) News
Follow Abbott Laboratories (ABT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 98 public stories across 32 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
US session market picture: S&P 500 -0.3%, Nasdaq 100 -1.56%; EUR/USD -0.16%, WTI +1.74%, WBD leads volume
US session market picture. US index futures: S and P futures is down 0.3 percent, Nasdaq futures is down 1.56 percent, Dow futures is up 0.48 percent and Russell futures is up 0.01 percent. In currencies, the dollar inde
EQUITY | Nov 05, 2026, 02:32 PM UTC
L
Daewoong Pharma Ends Abbott Drug Supply Deal in Four Southeast Asian Countries
Daewoong Pharma has terminated a drug export supply agreement with Abbott covering four Southeast Asian countries.
EQUITY | Nov 02, 2026, 09:59 AM UTC
L
Daewoong Pharma Ends KRW 69.23 Billion Southeast Asia Supply Deal With Abbott
Daewoong Pharma ended a supply deal with Abbott covering Southeast Asia, valued at KRW 69.23 billion.
EQUITY | Nov 02, 2026, 09:59 AM UTC
L
Abbott Says SonicForce Trial Meets Safety and Effectiveness Endpoints
Abbott said its experimental SonicForce device trial met its primary safety and effectiveness endpoints.
EQUITY | Nov 02, 2026, 09:35 AM UTC
L
FDA aprueba dispositivo de Abbott para tratar fugas en válvulas cardíacas reemplazadas
REGULATION | Oct 28, 2026, 01:12 PM UTC
M
Abbott receives FDA approval for heart valve leak treatment device
Abbott says the FDA approved its first device to treat leaks after heart valve replacement.
EQUITY | Oct 28, 2026, 01:06 PM UTC
M
Abbott to Spin Off Nutrition Business Into Independent Company
Abbott Laboratories said it will issue shares to existing investors for an independent company housing its Similac nutrition business.
EQUITY | Oct 21, 2026, 03:22 PM UTC
M
Abbott Plans to Separate Nutrition Business by End of Next Year
Abbott Laboratories plans to make its nutrition business an independent company by the end of next year.
MNA | Oct 21, 2026, 02:58 PM UTC
M
Abbott Laboratories Reports Quarterly Results
Abbott Laboratories reported results for the quarter ended September 30. The machine-generated summary provides no financial figures.
EQUITY | Oct 21, 2026, 01:32 PM UTC
M
Abbott Plans Tax-Free Distribution to Take Nutrition Co. Public
Abbott CFO Phil Boudreau says Nutrition Co. will go public through a planned tax-free distribution to Abbott shareholders.
MNA | Oct 21, 2026, 01:25 PM UTC
M
Abbott CEO Expects Sales Growth, Margins to Accelerate After Nutrition Spinoff
Abbott’s CEO expects the namesake company’s sales growth to accelerate and margin profiles to expand following the nutrition spinoff.
EQUITY | Oct 21, 2026, 01:23 PM UTC
M
Abbott CEO Says Portfolio Will Have Higher-Growth Mix After Nutrition Separation
Abbott's CEO said the portfolio will consist of a stronger mix of higher-growth, higher-margin businesses following the nutrition separation.
EQUITY | Oct 21, 2026, 01:22 PM UTC
M
Abbott CEO: 'As an Independent Company, Nutrition Will Be Uniquely Positioned to Capitalize on the Growing Demand for Healthy Nutrition'
Abbott CEO: 'As an Independent Company, Nutrition Will Be Uniquely Positioned to Capitalize on the Growing Demand for Healthy Nutrition'
EQUITY | Oct 21, 2026, 01:22 PM UTC
M
Abbott to Carve Out Nutrition Business After Strategic Review
CEO Robert Ford said the decision follows a comprehensive strategic review.
EQUITY | Oct 21, 2026, 01:16 PM UTC
M
Abbott Plans to Spin Off Nutrition Business Into Independent Company
Abbott plans to separate its nutrition business into an independent company with about $8.5 billion in annual sales.
MNA | Oct 21, 2026, 01:03 PM UTC
M
Abbott Plans to Separate Nutrition Business Into Independent Company
Abbott plans to separate its nutrition business into an independent company with about $8.5 billion in annual sales.
EQUITY | Oct 21, 2026, 12:25 PM UTC
M
Abbott Reports Third-Quarter Sales of $13.01 Billion, Up 14.5%
Abbott's comparable sales growth was 7.0%; reported diagnostics sales rose 46.7%.
EARNINGS | Oct 21, 2026, 12:16 PM UTC
M
Abbott narrows FY26 adjusted EPS guidance
Abbott reported Q3 financial results and narrowed its FY26 adjusted EPS guidance.
EQUITY | Oct 21, 2026, 12:14 PM UTC
H
$ABT Abbott Q3 2026 Earnings
Adj EPS $1.42, Est. $1.42 Net Sales $13.01B, Est. $13B Comparable Sales +7% Sees Q4 Adj EPS $1.62—$1.67 Reaffirms FY EPS Guidance Plans to Separate Global Nutrition Business Into Public Company by End-2027 Daniel Salvado
EARNINGS | Oct 21, 2026, 11:56 AM UTC
M
Abbott Reports Third-Quarter Adjusted EPS of $1.42
EARNINGS | Oct 21, 2026, 11:43 AM UTC
M
Abbott Plans to Spin Off Nutrition Business by End of 2027
Abbott plans to separate its global Nutrition business, with approximately $8.5 billion in sales, into an independent public company through a share distribution to Abbott shareholders. The plan is subject to approvals.
MNA | Oct 21, 2026, 11:43 AM UTC
M
Abbott Sees FY Adjusted EPS of $5.50-$5.55
EARNINGS | Oct 21, 2026, 11:31 AM UTC
M
Abbott Lowers 2026 Sales Growth Forecast to About 6%
Abbott lowered its 2026 sales growth forecast to about 6%, from a prior range of 6.5% to 7.5%, citing softer-than-expected demand for medical devices.
EARNINGS | Oct 21, 2026, 11:30 AM UTC
L
Abbott Labs Sees 4Q Adjusted EPS of $1.62-$1.67
EARNINGS | Oct 21, 2026, 11:30 AM UTC
M
Abbott Reports Third-Quarter Sales of $13.01 Billion
EARNINGS | Oct 21, 2026, 11:30 AM UTC
L
Abbott Labs Reports Third-Quarter EPS
EARNINGS | Oct 21, 2026, 11:30 AM UTC
M
Abbott Plans to Separate Global Nutrition Business
Abbott Laboratories said it plans to separate its nutrition business into an independent, publicly traded company.
EQUITY | Oct 21, 2026, 11:28 AM UTC
M
Abbott Intends to Separate Nutrition Business Into Public Company
Abbott announced its intention to separate its Nutrition business into an independent, publicly traded company.
MNA | Oct 21, 2026, 11:25 AM UTC
M
Abbott Laboratories Expected to Post Earnings of $1.42 a Share
An earnings preview expects Abbott Laboratories to report earnings of $1.42 per share.
EQUITY | Oct 19, 2026, 12:52 PM UTC
M
Abbott Q3'26 Earnings Preview
Abbott is scheduled to report Q3'26 results on October 21 before the market opens.
EQUITY | Oct 14, 2026, 11:00 AM UTC
M
Abbott schedules Q3 2026 earnings webcast and conference call
Abbott said it will announce third-quarter 2026 financial results on Oct. 21 before the market opens, followed by a live webcast of the earnings conference call at 8 a.m. CT (9 a.m. ET).
EQUITY | Sep 30, 2026, 01:00 PM UTC
L
Abbott (ABT) Launches FDA-Approved CRC Blood Test
Abbott launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for average-risk adults 45+, developed by Freenome and commercialized by Abbott. The test showed 81.1% CRC sensitivity and 90
REGULATION | Sep 30, 2026, 12:01 PM UTC
L
Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
ABBOTT PARK, Ill., Sept. 30, 2026 // -- Abbott (NYSE:ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults age 45 and older wh
REGULATION | Sep 30, 2026, 12:00 PM UTC
L
Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
ABBOTT PARK, Ill. and NEW YORK, Sept. 23, 2026 // -- Abbott (NYSE:ABT) and Berry Street today announced an exclusive partnership to help people take a more proactive approach to nutrition and long-term health. The partne
NEWS | Sep 23, 2026, 11:00 AM UTC
L
ABT - Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
ABT - Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
NEWS | Sep 23, 2026, 11:00 AM UTC
M
Grail shares surge after FDA staff see no major test concerns
US FDA staff reviewers said they did not raise major concerns about the accuracy and safety of Grail’s multi-cancer blood test. Grail’s shares surged 35% on Monday.
EQUITY | Sep 21, 2026, 04:41 PM UTC
H
Top News Today: Stocks Fall; AI Slowdown Fears Weigh on Tech; Oil Rises
MARKET WRAPSSTOCKS: Stocks fell amid fears that artificial-intelligence companies will slow development of the emerging technology.TREASURYS: Treasury yields fell but the yield on the 10-year note crossed the 5% level in
COMMODITIES | Sep 14, 2026, 08:39 PM UTC
M
Abbott agrees to $385 million settlement in baby formula case
Abbott Laboratories agreed to pay $385 million to settle allegations tied to its management of a baby formula facility, the U.S. Justice Department said.
REGULATION | Sep 14, 2026, 05:46 PM UTC
M
Abbott to pay about $385 million to resolve baby formula claims
Abbott Laboratories agreed to pay about $385 million to resolve U.S. allegations that it sold contaminated baby formula.
EQUITY | Sep 14, 2026, 04:31 PM UTC
H
Abbott agrees to DOJ settlement over 2022 infant formula recall
REGULATION | Sep 14, 2026, 03:57 PM UTC
L
Abbott (ABT) price target held at $135 by TD Cowen
Benzinga via TradingView reports TD Cowen maintained its price target for Abbott at $135.00 per share.
EQUITY | Sep 08, 2026, 02:07 PM UTC
M
Abbott gets FDA approval for TactiFlex Duo ablation catheter
Abbott Laboratories said it received FDA approval for its TactiFlex Duo ablation catheter to treat people with abnormal heart rhythms.
REGULATION | Sep 08, 2026, 01:10 PM UTC
M
Abbott wins FDA approval for TactiFlex Duo ablation catheter
Abbott announced it received U.S. FDA approval for the TactiFlex Duo Ablation Catheter, Sensor Enabled, to treat challenging atrial fibrillation (AFib) cases.
REGULATION | Sep 08, 2026, 12:03 PM UTC
L
Abbott CEO and Chairman sells shares worth over $46M
Abbott CEO and Chairman sold shares worth over $46M, according to TradingView News.
EQUITY | Aug 27, 2026, 09:21 PM UTC
L
Abbott Amulet 360™ gets CE mark for atrial fibrillation stroke treatment
Abbott’s Next-Generation Amulet 360™ device received CE mark to treat people with atrial fibrillation at risk of stroke.
EQUITY | Aug 27, 2026, 01:22 PM UTC
L
Abbott Amulet 360™ gets CE Mark for atrial fibrillation stroke-risk treatment
Abbott’s next-generation Amulet 360™ device received CE Mark to treat people with atrial fibrillation at risk of stroke.
EQUITY | Aug 27, 2026, 01:01 PM UTC
M
FDA clears Abbott Libre Duo 10-day dual glucose/ketone monitor
The FDA clears Abbott’s Libre Duo 10-day dual glucose ketone monitor, described as the first in the US to track ketones continuously.
REGULATION | Aug 25, 2026, 06:27 PM UTC
L
TD Cowen raises Abbott price target to $135 from $115
TD Cowen raises its price target on Abbott Laboratories to $135 from $115, with no additional catalyst supplied in the alert.
EQUITY | Aug 21, 2026, 10:00 AM UTC
H
Abbott (ABT) to pay about $670M to resolve gill, nec claims
Abbott (ABT) said it will pay about $670M to resolve gill case and nec claims, with about 1,700 lawsuits still pending involving claims for 12,700 infants.
REGULATION | Aug 20, 2026, 08:15 PM UTC
L
Abbott reaches agreements to resolve portion of specialty-formula litigation
Abbott says it has reached agreements to resolve a portion of litigation involving its specialty formulas for preterm infants, with no terms disclosed in the alert.
REGULATION | Aug 20, 2026, 08:15 PM UTC
L
Abbott reaches agreements to resolve Gill case, 2,000 related claims
Abbott says it has reached agreements to resolve the Gill case and 2,000 related claims.
REGULATION | Aug 20, 2026, 08:15 PM UTC
L
Abbott reaches agreements on preterm infant formula litigation
Abbott says it has reached agreements to resolve a portion of litigation involving its Specialty formulas for preterm infants.
REGULATION | Aug 20, 2026, 08:15 PM UTC
L
Abbott (ABT) and NACHC launch nationwide Food for Health initiative
Abbott (ABT) and NACHC have launched a nationwide Food for Health initiative aimed at making nutritious food a core part of healthcare.
REGULATION | Aug 17, 2026, 05:45 PM UTC
L
Rep. Mike Kelly discloses sales of ABT, DIS and PEP
Rep. Mike Kelly (R-Penn.) disclosed spouse-reported July 17 sales of Abbott Laboratories, Walt Disney and PepsiCo shares, plus a $50,000 to $100,000 municipal bond purchase.
REGULATION | Aug 13, 2026, 09:45 PM UTC
L
ABT: Abbott Revives Blood Donation Campaign
Abbott and Big Ten revive 'We Give Blood' amid US blood supply crisis
EQUITY | Aug 12, 2026, 01:15 PM UTC
H
Abbott Partners With Google Health To Combine Glucose Insights From Abbott's Lingo Biowearable With Google's Expertise In AI To Make Persona
The collaboration is designed to bring metabolic health insights into people's daily routines through a seamless, AI-powered experience. Through the Google Health app, Lingo users will be able to view glucose trends alon
EQUITY | Aug 11, 2026, 01:09 PM UTC
M
Abbott and Google Launch Partnership
Abbott partners with Google for health insights
EQUITY | Aug 11, 2026, 01:01 PM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC
L
FRNM +10% in pre-mkt ABT following earlier PR: Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Optio
FRNM +10% in pre-mkt ABT following earlier PR: Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment Link To P
REGULATION | Jul 27, 2026, 01:04 PM UTC
H
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth
EQUITY | Jul 27, 2026, 01:02 PM UTC